Denosumab is a humanized mAb that inhibits the activator of nuclear factor kappa-B ligand (RANKL) to prevent development of osteoclasts, the cells that break down bone. The originator drug, Amgen's ( AMGN ) Prolia/Xgeva was approved in the US in 2010, recording $5.6 billion in global revenues last year.